New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint and BluePrint Across Breast Cancer Patient Populations

November 30, 2017

IRVINE, CA, AMSTERDAM, NETHERLANDS – 30 November 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Cancer Symposium (SABCS), highlighting the value of its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test and BluePrint® Breast Cancer Molecular Subtyping…

Read more

Agendia’s MammaPrint Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code

November 28, 2017

CMS established the 2018 payment rate for MammaPrint’s new CPT code 81521 thus securing continued access to MammaPrint for Medicare/Medicaid beneficiaries The new determination and increased allowance follows an impressive Q3 which saw MammaPrint’s U.S. case volume grow by over 30% compared to the same period in 2016 IRVINE, CA, AMSTERDAM, NETHERLANDS – 28 November…

Read more

AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update

November 20, 2017

Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical evidence at the time of treatment In line with recent publications from NEJM and ASCO, the AJCC now recognizes MammaPrint with Level I evidence for determining clinical prognosis, which is the basis for chemotherapy treatment decisions…

Read more

New Study Published in JAMA Oncology Shows MammaPrint Changed Breast Cancer Treatment Decisions in 3 out of 4 Cases where Guidance was Unclear with the 21-Gene Assay

October 26, 2017

Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay’s intermediate range Physicians changed their treatment decisions in approximately 34% of all cases and in 76% of cases where treatment decisions were discordant based on the indication of the MammaPrint test, with 79% of physicians having…

Read more